Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05704361 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
A Phase 1 study of Multiple Sclerosis, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 129
- Enrollment target
- 20
- Study locations
NCT05704361: Recruiting Phase 1 study of Multiple Sclerosis, sponsored by Hoffmann-La Roche.
NCT05704361 is a Phase 1 study of Multiple Sclerosis that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 129 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05704361, a Phase 1 study of Multiple Sclerosis, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 129 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of the study is to evaluate the safety and tolerability of a single-ascending intravenous (IV) dose (Part 1), a single-ascending subcutaneous (SC) dose (Part 2), and multiple ascending SC doses (Part 3) of RO7121932 in participants with multiple sclerosis (MS).
Conditions Studied
Interventions
- DRUG RO7121932 IV
- DRUG RO7121932 SC
Study Locations (20)
Other
- Cliniques Universitaires St-Luc - Brussels
- UZ Gent - Ghent
- Universitätsklinikum "Carl Gustav Carus" - Dresden
- Universitätsmedizin Göttingen Georg-August-Universität - Göttingen
- Klinikum rechts der Isar der TU Muenchen - München
- Universitätsklinikum Münster Klinik u. Poliklinik f. Neurologie - Münster
- Universitätsklinikum Tübingen, Zentrum für Neurologie - Tübingen
- Universitätsklinikum Ulm - Ulm
- Hadassah University Hospital - Ein Kerem - Jerusalem
- Tel Aviv Sourasky Medical Center - Tel Aviv
- ARENSIA Exploratory Medicine Phase I, PMSI Republican Clinical Hospital - Chisinau
- Uniwersyteckie Centrum Kliniczne - Gda?sk
Lombardy
- IRCCS Ospedale San Raffaele - Milan
- Fond. Istituto Neurologico C.Besta - Milan
California
- Stanford University Medical Center - Stanford
Connecticut
- Yale University Multiple Sclerosis Center - New Haven
Florida
- University of South Florida - Tampa
Massachusetts
- University of Massachusetts Medical School - Worcester
Ohio
- UC Health, LLC. - Cincinnati
Quebec
- Montreal Neurological Institute and Hospital - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2021-08-11 |
| Est. Completion | 2027-07-08 |
| Phase | Phase 1 |
What NCT05704361 shows while recruiting
NCT05704361 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which RO7121932 IV is the first listed.
NCT05704361 names 20 study sites across 8 states, led by Other, Lombardy, California.
Frequently Asked Questions
What is clinical trial NCT05704361 about?
NCT05704361 is a clinical study titled "A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis". The primary purpose of the study is to evaluate the safety and tolerability of a single-ascending intravenous (IV) dose (Part 1), a single-ascending subcutaneous (SC) dose (Part 2), and multiple ascending SC doses (Part 3) of RO7121932 in participants with multiple sclerosis (MS).
What is the current status of trial NCT05704361?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 129 participants. The study started on 2021-08-11. Estimated completion is 2027-07-08.
What conditions does trial NCT05704361 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT05704361?
The interventions under investigation include: RO7121932 IV (DRUG), RO7121932 SC (DRUG).
Who is sponsoring clinical trial NCT05704361?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05704361 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05704361's enrollment target sits among peer trials
129 103rd of 315 higher than 212 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
RECRUITING · Phase 1
-
Molecular Imaging of NET Using [C-11]MRB-PET in MS
RECRUITING · Phase 1
-
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
- NCT06910943 · 129 participants · Phase 2
Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI